NCT05936489View on ClinicalTrials.gov

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

October 3, 2023

Study Completion Date

October 3, 2023

Conditions
Eye DiseasesPresbyopiaRefractive ErrorsBrimonidine TartrateAceclidineOphthalmic Solutions
Interventions
DRUG

Aceclidine + Brimonidine

LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution

DRUG

Aceclidine

LNZ100 (Aceclidine) non-preserved ophthalmic solution

Trial Locations (1)

92663

Site #101, Newport Beach

Sponsors
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

LENZ Therapeutics, Inc

OTHER

NCT05936489 - Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia | Biotech Hunter | Biotech Hunter